Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Capital Employed (2018 - 2025)

Crinetics Pharmaceuticals has reported Return on Capital Employed over the past 8 years, most recently at 48.02% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 1794.0% year-over-year to 48.02%; the TTM value through Dec 2025 reached 48.02%, down 1794.0%, while the annual FY2025 figure was 43.23%, 849.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 48.02% at Crinetics Pharmaceuticals, down from 40.89% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 28.1% in Q1 2025 and troughed at 70.84% in Q2 2023.
  • A 5-year average of 42.45% and a median of 40.35% in 2021 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: crashed -3226bps in 2023 and later skyrocketed 4004bps in 2024.
  • Year by year, Return on Capital Employed stood at 40.77% in 2021, then fell by -21bps to 49.26% in 2022, then increased by 24bps to 37.44% in 2023, then grew by 20bps to 30.09% in 2024, then tumbled by -60bps to 48.02% in 2025.
  • Business Quant data shows Return on Capital Employed for CRNX at 48.02% in Q4 2025, 40.89% in Q3 2025, and 33.65% in Q2 2025.